Effects of Oligo- Fucoidan on the Immune Response, Inflammatory Status and Pulmonary Function in Patients with Asthma
Phase 1
Completed
- Conditions
- Asthma.Asthma
- Registration Number
- TCTR20220624008
- Lead Sponsor
- Hi-Q Marine Biotech International Ltd
- Brief Summary
Oligo-fucoidan could reduce the proportion of lymphocytes and the concentration of inflammatory factors in patients with asthma to inhibit inflammation of the respiratory tract and increase pulmonary function.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
The inclusion criteria were (1) presence of allergic asthma, (2) absence of complicated underlying disease, (3) lack of history of upper or lower airway disease during the month before the study, and (4) not having received immunotherapy or oral or intravenous steroids during the four weeks before the study (inhaled steroids were allowed).
Exclusion Criteria
The exclusion criteria were malignancy, infection, pregnancy, and other systemic immune diseases.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Oligo-fucoidan could inhibit inflammation after treatment 12 weeks and 24 weeks Analysis of the levels of cytokines,increase pulmonary function after treatment 12 weeks and 24 weeks asthma control test
- Secondary Outcome Measures
Name Time Method increase pulmonary function after treatment 12 weeks and 24 weeks Lung function test